Questions From the Literature

What is BPC-157 and where did it come from?

BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV, molecular weight 1419.55 Da, and CAS number 137525-51-0. The sequence is a partial fragment of a larger cytoprotective protein that was identified in human gastric juice in the early 1990s. The full name Body Protection Compound 157 — and the descriptor stable gastric pentadecapeptide — both encode the molecule’s origin and its defining property: it appears to resist gastric proteolysis, which is unusual for a peptide. The triple-proline tract at positions 3–5 is generally credited with the stability. The peptide has been studied under several development-program codes: PL 14736, PL-10, and PLD-116, all referring to the same compound in different industry registries.

Is BPC-157 used in any clinical trials?

There is no actively recruiting BPC-157 trial in any major international registry as of this writing. Three small uncontrolled pilot reports have been published by a single investigator group between 2021 and 2025: an intra-articular knee case series in 16 patients, an intravesicular bladder injection series of 12 women with interstitial cystitis, and a single-arm intravenous infusion in healthy volunteers^[17]. The only registered Phase I trial — ClinicalTrials.gov NCT02637284, PCO-02 in healthy volunteers — was listed in 2015 and cancelled in 2016 without published results.

What kinds of clinical research settings have studied BPC-157?

The only formal clinical-development program of record is the Pliva (Croatia) PL 14736 enema program for mild-to-moderate ulcerative colitis, a multicenter randomized double-blind placebo-controlled Phase II trial reported as completed in the mid-2000s^[6]. The trial was reported as safe and well tolerated; full efficacy data were never published in a peer-reviewed paper and the program did not advance.

The three published human pilot reports of the last five years (knee, bladder, IV) are case-series-level, not controlled trials, and all are from one investigator group^[17]. Outside of those, the BPC-157 literature is preclinical.

Has BPC-157 ever reached a human Phase II trial?

Yes — once. The Pliva PL 14736 program for ulcerative colitis was advanced to Phase II as a rectal enema formulation, run as a multicenter randomized double-blind placebo-controlled trial^[6]. The program was reported as safe and well tolerated. Full efficacy data were never published in a standalone peer-reviewed paper, and the program was not advanced further. To our reading no other BPC-157 program has reached Phase II.

What is the FDA’s position on BPC-157?

BPC-157 is not approved by the FDA for any human indication. In September 2023 the FDA placed BPC-157 on its Category 2 list of bulk drug substances that may present significant safety risks under section 503A of the Food, Drug, and Cosmetic Act. Category 2 status effectively excludes BPC-157 from 503A pharmacy compounding for human use^[18]. The FDA has also issued public statements identifying BPC-157 as an unapproved drug found in some wellness products. The 2025 HSS Journal systematic review explicitly notes the Category 2 listing^[16].

Is BPC-157 banned by WADA, and under which category?

Yes. BPC-157 is prohibited by the World Anti-Doping Agency under section S0 — Non-Approved Substances of the Prohibited List. The 2022 Prohibited List, in force from 1 January 2022, named BPC-157 explicitly as the first such named example under S0; the prohibition has remained in subsequent annual lists^[16][18]. Prohibition applies in and out of competition. There is no Therapeutic Use Exemption pathway under S0 because the category by definition covers substances without an approved human therapeutic indication. USADA, the IOC, NCAA, NFL, NBA, NHL, MLB, and most major professional and amateur sports bodies follow the WADA Prohibited List.

What doses of BPC-157 are used in the research literature?

The dominant rodent dose pairing is 10 μg/kg and 10 ng/kg, run side-by-side, and reported with comparable effects across many studies^{[1][3][4][7][8][10][13][14][15][19][23]}. Elevated rodent doses include 200 μg/kg in the Perovic et al. (2019) spinal cord injury model^[9] and 20 μg/kg in the Demirtas et al. (2025) ischemia-reperfusion study^[12]. In vitro work uses 0.1–0.5 μg/mL in cell culture media^[2]. Drinking-water arms typically run at 0.16 μg/mL or 0.16 ng/mL to deliver approximately 10 μg/kg/day or 10 ng/kg/day in rats^[14]. Rabbit segmental bone-defect work used 10 μg/kg^[5]. Dog pharmacokinetic work used 6–150 μg/kg intramuscular^[11]. The three published human pilot reports used variable formulations: intra-articular knee, 10 mg intravesicular bladder, and up to 20 mg intravenous^[17].

How is BPC-157 typically administered in studies?

Rodent studies have administered the peptide by intraperitoneal injection, intragastric gavage, peroral administration in drinking water, subcutaneous injection, intramuscular injection, topical cream (1 μg/g), and local injection at the injury site. Peroral administration via drinking water is unusual for a peptide and is justified in the source literature by the molecule’s reported stability in gastric juice. The three human pilot reports added intravenous infusion, intra-articular knee injection, and intravesicular bladder injection^[17]. The historical Pliva PL 14736 Phase II program used a rectal enema formulation^[6].

What does the research say about BPC-157 and tendon healing?

The tendon literature is one of the better-developed branches of the BPC-157 record. Staresinic et al. (2003) reported that transected Achilles tendons in Sprague-Dawley rats treated with 10 μg/kg or 10 ng/kg intraperitoneal showed increased load-to-failure, superior collagen and reticulin organization, and full restoration of tendon integrity; in parallel, 4-hydroxynonenal-induced growth inhibition of cultured tendocytes was reversed into stimulation^[1]. Krivic et al. (2006) reported that the peptide promoted tendon-to-bone healing in an Achilles detachment model and counteracted the negative effect of concomitant corticosteroid (methylprednisolone)^[3]. Chang et al. (2014) reported in vitro that BPC-157 upregulated growth hormone receptor expression in tendon fibroblasts up to sevenfold and amplified proliferation when co-incubated with growth hormone via JAK2 activation^[2]. The 2025 HSS Journal systematic review identified tendon, ligament, muscle, and bone preclinical signals as broad but human evidence as minimal^[16].

What does the research say about BPC-157 and gut or IBD?

The gastrointestinal literature is the oldest branch of BPC-157 research and gives the peptide its name. Rat ulcerative-colitis-style models (cysteamine, vascular-occlusion-related) report reduced colonic ulceration, edema, and inflammatory infiltrate with BPC-157 at 10 μg/kg or 10 ng/kg^[24]. The 2024 review by Bajramagic et al. catalogues rat intestinal anastomosis studies across esophagogastric, colocolonic, jejunoileal, and ileoileal segments with reduced leakage and increased burst pressure^[13]. Fistula closure has been reported in colocutaneous^[7], duodenocolic^[19], and tracheocutaneous models^[23]. The Pliva PL 14736 Phase II enema program for mild-to-moderate ulcerative colitis is the only human IBD trial of record and was reported as safe and well tolerated but never published in full^[6].

What are the safety findings for BPC-157 in animal studies?

Acute toxicology summarized in the 2025 Pharmaceuticals review by Jozwiak et al. reports no observed teratogenic, genotoxic, anaphylactic, or local toxic effects at the high doses tested — Sprague-Dawley rats up to 20 mg/kg intramuscular and beagle dogs up to 10 mg/kg intramuscular^[18]. The same review flags theoretical concerns: VEGFR2-mediated angiogenesis could be problematic in malignant or pre-malignant settings, proline metabolites can activate proline oxidase and generate reactive oxygen species, and excessive nitric oxide production may impair drug metabolism and contribute to neurotoxicity. The 2025 Inflammopharmacology commentary describes the peptide as having apparently low toxicity in the doses tested but flags unresolved questions on structure-activity relationships and pharmacogenetics. None of this resolves the human safety question, because controlled human safety data do not exist at scale.

Why is most BPC-157 research in rats rather than humans?

Three reasons converge. First, regulatory: BPC-157 has not been approved by any major regulatory authority for any human indication, which constrains the pathway to human studies. The FDA Category 2 listing in 2023 further restricted pharmacy compounding^[18]. Second, structural: almost all key musculoskeletal and gastrointestinal papers come from a single research lab — Predrag Sikiric’s group at the University of Zagreb — and that group has not historically led human clinical-development work. The Pliva PL 14736 ulcerative colitis program reached Phase II in the mid-2000s and stopped^[6]. Third, the broader peptide-research economics have not produced a sponsor willing to advance BPC-157 through controlled human trials despite the breadth of the preclinical record. The 2025 systematic review by Vasireddi et al. in HSS Journal states the ratio plainly: thirty-five preclinical to one clinical out of thirty-six indexed articles between 1993 and 2024^[16].

Is BPC-157 a peptide, a drug, or a supplement?

BPC-157 is a synthetic peptide. It is not an approved drug under any major regulatory authority. It is not a dietary supplement under U.S. FDA rules — peptides of this kind do not qualify under DSHEA, and the FDA has issued statements identifying BPC-157 as an unapproved drug found in some wellness products. It is sold over the internet as a research chemical or research peptide, often mislabeled as a supplement. The FDA Category 2 listing of September 2023 prohibits its use in 503A pharmacy compounding^[18]. Product quality, identity, and purity have been reported as highly variable across non-pharmacy sources.

What is the half-life and bioavailability of BPC-157?

He et al. (2022), publishing in Frontiers in Pharmacology, reported intramuscular bioavailability of 14–19% in Sprague-Dawley rats and 45–51% in beagle dogs across dose ranges of 20–500 μg/kg (rat) and 6–150 μg/kg (dog)^[11]. Peak plasma concentration (T_max) was reached at approximately 3 minutes in rats and 6–9 minutes in dogs. Plasma half-life was under 30 minutes in both species after intramuscular dosing. The peptide is metabolized into six small fragments terminating in free amino acids, with proline notable among them; elimination occurs in urine and bile. Oral bioavailability is presumed by stability in gastric juice but has not been formally quantified in healthy humans.